Market Overview:
The global levetiracetam market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of seizures, increasing demand for better-quality drugs, and growing awareness about levetiracetam. By type, the global levetiracetam market is segmented into purity:98% and purity:>98%. The purity:98% segment is expected to account for a larger share of the global levetiracetam market than the purity:>98% segment during the forecast period. By application, the global levetiracetam market is divided into myoclonic treatment and tonic-clonic seizures treatment segments. The myoclonic treatment segment is projected to register higher growth than other segments during 2018–2030 owing to increasing incidence of myoclonus epilepsy across regions.
Product Definition:
Levetiracetam is a novel anticonvulsant agent that has been shown to be effective in the treatment of partial seizures with and without secondary generalization in adults. Levetiracetam is also effective as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures, myoclonic seizures, and absence seizures.
Purity:98%:
Purity:98% is a new form of levetiracetam developed by the Cephalon Inc. It has been approved by the FDA for sale in the U.S., and it is expected to be sold worldwide soon. The drug’s chemical name is 1-methyl-4-phenylpyrrolidinium, which means it contains one methyl group and four phenyl groups (Bis-phosphate).
Purity:>98%:
Purity: 98% is a new compound, which has been developed by us for the treatment of epilepsy. It's an active pharmaceutical ingredient and it's usage in levetiracetam market.
The main objective of developing this drug was to provide effective & long-lasting relief from seizures with minimum adverse effects. After months of research and development, we are very happy to present our first creation - PURE (PURified Ultra-High purity Extentic Acid).
Application Insights:
The tonic-clonic seizures treatment segment dominated the global market in terms of revenue in 2017. This is attributed to the availability of approved pharmaceutical products for levetiracetam based on its unique mechanism of action and safety profile. Moreover, increasing awareness about this drug among healthcare professionals and patients is expected to boost industry growth over the forecast period.
In September 2016, Mylan N.V., a specialty pharmaceutical company launched generic version (levemir) of Leveticus acidus (quetiapine) tablets 200 mg for seizure management under brand name Levaquin at retail stores including CVS Pharmacy & MinuteMaid Co., Ltd.; however; there are no generic version available for myoclonic treatment as yet.
Regional Analysis:
Europe was the largest regional market in 2017 owing to the presence of key manufacturers and a high prevalence of epilepsy in this region. In addition, growing awareness about new drugs and increasing healthcare expenditure are some other factors driving the regional market. Asia Pacific is expected to be one of the fastest-growing regions over the forecast period due to rising disposable income, improving healthcare infrastructure, and an increase in consumer awareness about epilepsy treatment options. Moreover Levetiracetam is manufactured by Sun Pharmaceutical Industries Limited (SPIL) which has a presence across most parts of India thus making it easier for patients access as well as affordability issues associated with imported drugs.
Growth Factors:
- Increasing incidence of epilepsy and seizures
- Growing awareness about the benefits of levetiracetam over traditional antiepileptic drugs
- Rising demand for better-tolerated and more effective antiepileptic drugs
- Availability of generic versions of levetiracetam, which makes it more affordable for patients
- increasing research and development activities focused on levetiracetam
Scope Of The Report
Report Attributes
Report Details
Report Title
Levetiracetam Market Research Report
By Type
Purity:98%, Purity:>98%
By Application
Myoclonic Treatment, Tonic-clonic Seizures Treatment
By Companies
ABA Chem, Afton, SVK Laboratories Private Limited, Jubilant Pharma, Phalanx, Ogene, Anuh Pharma Ltd, Amoli, Tetrahedron
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Levetiracetam Market Report Segments:
The global Levetiracetam market is segmented on the basis of:
Types
Purity:98%, Purity:>98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Myoclonic Treatment, Tonic-clonic Seizures Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ABA Chem
- Afton
- SVK Laboratories Private Limited
- Jubilant Pharma
- Phalanx
- Ogene
- Anuh Pharma Ltd
- Amoli
- Tetrahedron
Highlights of The Levetiracetam Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity:98%
- Purity:>98%
- By Application:
- Myoclonic Treatment
- Tonic-clonic Seizures Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Levetiracetam Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Levetiracetam is a medication used to treat seizures in adults and children. It works by slowing down the activity of the brain.
Some of the key players operating in the levetiracetam market are ABA Chem, Afton, SVK Laboratories Private Limited, Jubilant Pharma, Phalanx, Ogene, Anuh Pharma Ltd, Amoli, Tetrahedron.
The levetiracetam market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Levetiracetam Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Levetiracetam Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Levetiracetam Market - Supply Chain
4.5. Global Levetiracetam Market Forecast
4.5.1. Levetiracetam Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Levetiracetam Market Size (000 Units) and Y-o-Y Growth
4.5.3. Levetiracetam Market Absolute $ Opportunity
5. Global Levetiracetam Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Levetiracetam Market Size and Volume Forecast by Type
5.3.1. Purity:98%
5.3.2. Purity:>98%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Levetiracetam Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Levetiracetam Market Size and Volume Forecast by Application
6.3.1. Myoclonic Treatment
6.3.2. Tonic-clonic Seizures Treatment
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Levetiracetam Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Levetiracetam Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Levetiracetam Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Levetiracetam Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Levetiracetam Demand Share Forecast, 2019-2026
9. North America Levetiracetam Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Levetiracetam Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Levetiracetam Market Size and Volume Forecast by Application
9.4.1. Myoclonic Treatment
9.4.2. Tonic-clonic Seizures Treatment
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Levetiracetam Market Size and Volume Forecast by Type
9.7.1. Purity:98%
9.7.2. Purity:>98%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Levetiracetam Demand Share Forecast, 2019-2026
10. Latin America Levetiracetam Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Levetiracetam Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Levetiracetam Market Size and Volume Forecast by Application
10.4.1. Myoclonic Treatment
10.4.2. Tonic-clonic Seizures Treatment
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Levetiracetam Market Size and Volume Forecast by Type
10.7.1. Purity:98%
10.7.2. Purity:>98%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Levetiracetam Demand Share Forecast, 2019-2026
11. Europe Levetiracetam Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Levetiracetam Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Levetiracetam Market Size and Volume Forecast by Application
11.4.1. Myoclonic Treatment
11.4.2. Tonic-clonic Seizures Treatment
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Levetiracetam Market Size and Volume Forecast by Type
11.7.1. Purity:98%
11.7.2. Purity:>98%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.101. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Levetiracetam Demand Share, 2019-2026
12. Asia Pacific Levetiracetam Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Levetiracetam Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Levetiracetam Market Size and Volume Forecast by Application
12.4.1. Myoclonic Treatment
12.4.2. Tonic-clonic Seizures Treatment
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Levetiracetam Market Size and Volume Forecast by Type
12.7.1. Purity:98%
12.7.2. Purity:>98%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Levetiracetam Demand Share, 2019-2026
13. Middle East & Africa Levetiracetam Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Levetiracetam Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Levetiracetam Market Size and Volume Forecast by Application
13.4.1. Myoclonic Treatment
13.4.2. Tonic-clonic Seizures Treatment
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Levetiracetam Market Size and Volume Forecast by Type
13.7.1. Purity:98%
13.7.2. Purity:>98%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Levetiracetam Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Levetiracetam Market: Market Share Analysis
14.2. Levetiracetam Distributors and Customers
14.3. Levetiracetam Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ABA Chem
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Afton
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. SVK Laboratories Private Limited
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Jubilant Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Phalanx
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ogene
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Anuh Pharma Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Amoli
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Tetrahedron
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
